Insider Selling: SOPHiA GENETICS (NASDAQ:SOPH) CTO Sells $42,906.08 in Stock

Posted by Francis Steltz on Oct 10th, 2026

SOPHiA GENETICS SA (NASDAQ:SOPH – Get Free Report) CTO Abhimanyu Verma sold 5,284 shares of the business’s stock in a transaction on Monday, October 5th. The shares were sold at an average price of $8.12, for a total value of $42,906.08. Following the completion of the sale, the chief technology officer directly owned 166,887 shares in the company, valued at approximately $1,355,122.44. This represents a 3.07% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Abhimanyu Verma also recently made the following trade(s):

On Monday, August 24th, Abhimanyu Verma sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $8.80, for a total value of $44,000.00.
On Wednesday, August 19th, Abhimanyu Verma sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $8.20, for a total value of $41,000.00.
On Friday, August 7th, Abhimanyu Verma sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $7.60, for a total value of $38,000.00.
On Tuesday, August 4th, Abhimanyu Verma sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $6.95, for a total transaction of $34,750.00.

SOPHiA GENETICS Stock Up 1.5%

SOPH opened at $7.41 on Friday. The firm’s 50-day simple moving average is $7.91 and its 200-day simple moving average is $6.16. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.55 and a current ratio of 2.69. SOPHiA GENETICS SA has a twelve month low of $3.75 and a twelve month high of $8.98. The firm has a market cap of $621.62 million, a price-to-earnings ratio of -6.44 and a beta of 0.95.

SOPHiA GENETICS (NASDAQ:SOPH – Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.05). The firm had revenue of $23.31 million for the quarter, compared to the consensus estimate of $21.72 million. SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. Equities research analysts anticipate that SOPHiA GENETICS SA will post -0.77 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. HC Wainwright lifted their target price on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Zacks Research raised SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st. BTIG Research lifted their price objective on SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Friday, July 17th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, SOPHiA GENETICS currently has an average rating of “Hold” and a consensus target price of $10.00.

Get Our Latest Analysis on SOPHiA GENETICS

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of SOPH. AWM Investment Company Inc. acquired a new stake in shares of SOPHiA GENETICS in the 2nd quarter valued at $9,809,000. Principal Financial Group Inc. lifted its stake in shares of SOPHiA GENETICS by 0.7% during the first quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock valued at $6,976,000 after acquiring an additional 9,800 shares during the period. Hodges Capital Management Inc. bought a new position in SOPHiA GENETICS in the first quarter valued at about $2,157,000. Sei Investments Co. bought a new position in SOPHiA GENETICS in the first quarter valued at about $1,772,000. Finally, 1492 Capital Management LLC boosted its holdings in SOPHiA GENETICS by 8.4% in the first quarter. 1492 Capital Management LLC now owns 225,751 shares of the company’s stock valued at $1,117,000 after acquiring an additional 17,406 shares during the last quarter. Institutional investors and hedge funds own 31.59% of the company’s stock.

About SOPHiA GENETICS

(Get Free Report)

SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.

The company’s principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.